Natural innate and adaptive immunity to cancer.

  title={Natural innate and adaptive immunity to cancer.},
  author={Matthew D. Vesely and Michael H. Kershaw and Robert D. Schreiber and Mark J. Smyth},
  journal={Annual review of immunology},
The immune system can identify and destroy nascent tumor cells in a process termed cancer immunosurveillance, which functions as an important defense against cancer. Recently, data obtained from numerous investigations in mouse models of cancer and in humans with cancer offer compelling evidence that particular innate and adaptive immune cell types, effector molecules, and pathways can sometimes collectively function as extrinsic tumor-suppressor mechanisms. However, the immune system can also… 

Innate immune mediators in cancer: between defense and resistance

Recent advances in the understanding of the role of cell populations and soluble components of the innate immune system in cancer, with a focus on complement, the adapter molecule Stimulator of Interferon Genes, natural killer cells, myeloid cells, and B cells are reviewed.

Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic Approaches

Cells of myeloid origin with strong immunosuppressive and tumor-promoting properties, such as myeloids-derived suppressor cells (MDSCs) and tumors-associated macrophages (TAMs), are major players in this process.

Role of Innate Immunity in Cancers and Antitumor Response

Innate immune system serves as the first line of defense against pathogens and cancers. In tumors, innate immune cells are attracted into the tumor site, where they can recognize the transformed

TGF-beta: a master switch in tumor immunity.

Mechanisms through which TGF-β interferes with the development of an anti-tumor immunity and potential means through which to circumvent its activity in order to define more effective cancer immunotherapies are discussed.

Inflammation and immune surveillance in cancer.

The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance

The role of innate immunity as a positive and negative regulator of adaptive immunosurveillance is discussed and how tumor cells may skew leukocytes toward an immunosuppressive state and, as such, subvert the phenotypic plasticity of the immune compartment to advance disease progression is highlighted.

Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy

If the immune balance of disseminated BC cell dormancy (equilibrium phase) is lost, distant metastatic relapse may occur and the mechanisms of immune evasion leading to tumor progression are dissected.

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

A unifying conceptual framework called “cancer immunoediting,” which integrates the immune system’s dual host-protective and tumor-promoting roles is discussed.

Innate lymphoid cells in early tumor development

Emerging evidence that shows that ILCs can impact early tumor development by regulating immune responses against transformed cells, as well as the environmental cues that potentially induce ILC activation in premalignant lesions are discussed.



Immune surveillance of tumors.

This work provides the basis for further study of natural immunity to cancer and for rational use of this information in the design of immunotherapies in combination with other conventional cancer treatments.

Immunoregulatory T cells in tumor immunity.

The three Es of cancer immunoediting.

The history of the cancer immunosurveillance controversy is summarized and its resolution and evolution into the three Es of cancer immunoediting--elimination, equilibrium, and escape are discussed.

Interferons, immunity and cancer immunoediting

The roles of the IFNs are discussed, not only in cancer immunosurveillance but also in the broader process of cancer immunoediting.

The Anti-Tumor Activity of IL-12: Mechanisms of Innate Immunity That Are Model and Dose Dependent1

Overall, both NK and NKT cells can contribute to natural and IL-12-induced immunity against tumors, and the relative role of each population is tumor and therapy dependent.

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

A previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs) is described.

A critical function for type I interferons in cancer immunoediting

It is shown that, like IFN-γ, endogenously producedIFN-α/β was required for the prevention of the growth of primary carcinogen–induced and transplantable tumors.